Cargando…
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study
Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs. Although some studies compared the efficacies of treatment switch from ETV to TAF, there has been no r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524959/ https://www.ncbi.nlm.nih.gov/pubmed/36181074 http://dx.doi.org/10.1097/MD.0000000000030630 |
_version_ | 1784800604347957248 |
---|---|
author | Sato, Kosuke Inoue, Jun Akahane, Takehiro Kobayashi, Tomoo Sato, Shuichi Kisara, Norihiro Ninomiya, Masashi Iwata, Tomoaki Sano, Akitoshi Tsuruoka, Mio Onuki, Masazumi Masamune, Atsushi |
author_facet | Sato, Kosuke Inoue, Jun Akahane, Takehiro Kobayashi, Tomoo Sato, Shuichi Kisara, Norihiro Ninomiya, Masashi Iwata, Tomoaki Sano, Akitoshi Tsuruoka, Mio Onuki, Masazumi Masamune, Atsushi |
author_sort | Sato, Kosuke |
collection | PubMed |
description | Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs. Although some studies compared the efficacies of treatment switch from ETV to TAF, there has been no randomized study. METHODS: We performed a prospective multicenter randomized controlled study in which subjects were enrolled from April 2018 to June 2019 and observed for 2 years until March 2021 to clarify the efficacy and safety of switching from ETV to TAF. RESULTS: Thirty-three patients were enrolled and randomized into 2 groups, and a total of 30 patients were evaluated; a TAF-switching group (n = 16) and an ETV-continuing group (n = 14). The mean age of the 30 patients was 61 years old and 18 patients (60%) were male. The serum HBV DNA in all patients were below detection limit. The mean change in hepatitis B surface antigen (HBsAg) levels after 2 years was not significantly different between the TAF and ETV groups (–0.08 vs –0.20 log IU/mL, P = .07). Comparing the group with a HBsAg decline (≤ –0.1 log IU/mL) and a group without a HBsAg decline in an overall analysis, the prior ETV duration was significantly shorter in the HBsAg-declined group (49 vs 92 months, P = .03). Although the eGFR levels tended to decrease in the TAF group compared to ETV (–6.15 vs –2.26 mL/min/1.73 m(2), P = .09), no significant differences were observed in patients with baseline eGFR < 60 (–2.49 vs 0.40 mL/min/1.73 m(2), P = .25). CONCLUSION: The efficacy and safety were comparable in the TAF-switching group and the ETV-continuing group. Because the present study was conducted in limited patients, a larger study will be required. |
format | Online Article Text |
id | pubmed-9524959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95249592022-10-03 Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study Sato, Kosuke Inoue, Jun Akahane, Takehiro Kobayashi, Tomoo Sato, Shuichi Kisara, Norihiro Ninomiya, Masashi Iwata, Tomoaki Sano, Akitoshi Tsuruoka, Mio Onuki, Masazumi Masamune, Atsushi Medicine (Baltimore) Research Article Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs. Although some studies compared the efficacies of treatment switch from ETV to TAF, there has been no randomized study. METHODS: We performed a prospective multicenter randomized controlled study in which subjects were enrolled from April 2018 to June 2019 and observed for 2 years until March 2021 to clarify the efficacy and safety of switching from ETV to TAF. RESULTS: Thirty-three patients were enrolled and randomized into 2 groups, and a total of 30 patients were evaluated; a TAF-switching group (n = 16) and an ETV-continuing group (n = 14). The mean age of the 30 patients was 61 years old and 18 patients (60%) were male. The serum HBV DNA in all patients were below detection limit. The mean change in hepatitis B surface antigen (HBsAg) levels after 2 years was not significantly different between the TAF and ETV groups (–0.08 vs –0.20 log IU/mL, P = .07). Comparing the group with a HBsAg decline (≤ –0.1 log IU/mL) and a group without a HBsAg decline in an overall analysis, the prior ETV duration was significantly shorter in the HBsAg-declined group (49 vs 92 months, P = .03). Although the eGFR levels tended to decrease in the TAF group compared to ETV (–6.15 vs –2.26 mL/min/1.73 m(2), P = .09), no significant differences were observed in patients with baseline eGFR < 60 (–2.49 vs 0.40 mL/min/1.73 m(2), P = .25). CONCLUSION: The efficacy and safety were comparable in the TAF-switching group and the ETV-continuing group. Because the present study was conducted in limited patients, a larger study will be required. Lippincott Williams & Wilkins 2022-09-30 /pmc/articles/PMC9524959/ /pubmed/36181074 http://dx.doi.org/10.1097/MD.0000000000030630 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | Research Article Sato, Kosuke Inoue, Jun Akahane, Takehiro Kobayashi, Tomoo Sato, Shuichi Kisara, Norihiro Ninomiya, Masashi Iwata, Tomoaki Sano, Akitoshi Tsuruoka, Mio Onuki, Masazumi Masamune, Atsushi Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study |
title | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study |
title_full | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study |
title_fullStr | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study |
title_full_unstemmed | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study |
title_short | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study |
title_sort | switching to tenofovir alafenamide versus continued therapy in chronic hepatitis b patients who were treated with entecavir: a prospective, multicenter, randomized controlled study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524959/ https://www.ncbi.nlm.nih.gov/pubmed/36181074 http://dx.doi.org/10.1097/MD.0000000000030630 |
work_keys_str_mv | AT satokosuke switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT inouejun switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT akahanetakehiro switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT kobayashitomoo switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT satoshuichi switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT kisaranorihiro switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT ninomiyamasashi switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT iwatatomoaki switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT sanoakitoshi switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT tsuruokamio switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT onukimasazumi switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy AT masamuneatsushi switchingtotenofoviralafenamideversuscontinuedtherapyinchronichepatitisbpatientswhoweretreatedwithentecaviraprospectivemulticenterrandomizedcontrolledstudy |